Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.87 |
| ▸ | ACHE | P22303 | 6/20 | 0.74 |
| ▸ | BCHE | P06276 | 3/20 | 0.74 |
| ▸ | CES2 | O00748 | 2/20 | 0.68 |
| ▸ | MIF | P14174 | 5/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | MAOA | P21397 | 5/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787095 | 1.00 | MAOB (0.87) | MAOBACHEBCHECES2MIF | |
| SCHEMBL30667154 | 1.00 | MAOB (0.87) | MAOBACHEBCHECES2MIF | |
| SCHEMBL5582417 | 0.93 | MAOB (1.00) | MAOBACHEBCHECES2MIF | |
| SCHEMBL5582418 | 0.93 | MAOB (1.00) | MAOBACHEBCHECES2MIF | |
| SCHEMBL14524721 | 0.93 | MAOB (1.00) | MAOBACHEBCHECES2MIF | |
| SCHEMBL29038294 | 0.92 | CES2 (0.80) | MAOBACHEBCHECES2MIF | |
| SCHEMBL29038289 | 0.92 | CES2 (0.80) | MAOBACHEBCHECES2MIF | |
| SCHEMBL29038272 | 0.86 | CES2 (0.69) | MAOBACHEBCHECES2MIF | |
| SCHEMBL29038270 | 0.86 | CES2 (0.69) | MAOBACHEBCHECES2MIF | |
| SCHEMBL8010257 | 0.84 | ACHE (0.74) | MAOBACHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220053-B1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-11 | — | — | EP | disclosed |
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055548-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| EP-0848699-B1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5998451-A | LIPOXYGENASE INHIBITORS | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
| US-5922771-A | MELATONIN RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0848699-A1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997005098-A1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-13 | — | — | WO | disclosed |
| EP-0313295-B1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES | PFIZER INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | ADORA2A, ADORA2B, ADORA3 | MAOB 68/4885ACHE 977/4885BCHE 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.